Please login to the form below

Not currently logged in
Email:
Password:

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost
Yitzhak Peterburg

The Teva board has elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost who is due to step down at the end of the year.

Peterburg has worked at Teva since 2009 and has been group VP head of global branded products for the firm since 2010.

His career also includes spells as CEO and president at telecoms company Cellcom Israel and CEO at Clalit Health Services, Israel's leading healthcare provider.

Frost, who was appointed chairman since, March 2010, has overseen an era of change for Teva as it looks to move beyond its generics background and build its specialty pharmaceuticals business.

Frost was said to have a strained relationship with Teva's former CEO Jeremy Levin who left the company in 2013 to be replaced by Erez Vigodman at the beginning of 2014.

Teva also appointed Sol Barer, the former chief executive of Celgene, as a director.

28th November 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics